Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway

Miao,Jin-Hao; Wang,Shu-Qiang; Zhang,Ming-Hui; Yu,Feng‑Bin; Zhang,Lei; Yu,Zhong-Xiang; Kuang,Yong

doi:10.3892/or.2014.3358

Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway

Authors:
- Jin-Hao Miao
- Shu-Qiang Wang
- Ming-Hui Zhang
- Feng‑Bin Yu
- Lei Zhang
- Zhong-Xiang Yu
- Yong Kuang
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China, Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China, Department of Orthopaedic Surgery, No. 98 Hospital of PLA, Huzhou, Zhejiang, P.R. China
Published online on: July 24, 2014 https://doi.org/10.3892/or.2014.3358
Pages: 1497-1504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galectin-1 (GAL1), a widely expressed β‑galactoside-binding protein, exerts pleiotropic biological functions. GAL1 has been found to be upregulated in many malignancies; yet the role of GAL1 in the pathophysiology of human osteosarcoma (OS) remains uncertain. The present study was carried out to investigate the expression of GAL1 in human OS tissues and to explore its effects on the growth and invasion of OS cells. OS and corresponding adjacent non-cancerous tissues (ANCT) were collected from 30 consecutive cases. The expression of GAL1 was detected by immunohistochemical assay through tissue microarray procedure. Using small hairpin RNA (shRNA)-mediated GAL1 knockdown (Lv-shGAL1) in OS (MG-63 and U-2 OS) cells, we observed the changes in the malignant phenotype in OS cells in vitro and in vivo. As a consequence, the positive expression of GAL1 was significantly higher in OS tissues than that in the ANCT (63.3 vs. 36.7%, P=0.029), and was positively correlated with distant metastasis in the OS patients (P=0.022). Knockdown of GAL1 suppressed cell proliferative activities and invasive potential and induced apoptosis in OS cells with decreased expression of p38MAPK, p-ERK, Ki-67 and matrix metallopeptidase-9 (MMP-9) and increased expression of caspase-3. In addition, the tumor volume in the MG-63 subcutaneous tumor models treated with Lv-shGAL1 was significantly smaller than that in the negative control (NC) group (P<0.01). Altogether, our findings indicate that high expression of GAL1 is associated with distant metastasis of OS patients, and knockdown of GAL1 inhibits growth and invasion of OS cells possibly through inhibition of the MAPK/ERK pathway, suggesting that GAL1 may represent a potential target for the treatment of cancer.

View Figures

View References

1	Carrle D and Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop. 30:445–451. 2006. View Article : Google Scholar : PubMed/NCBI
2	Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar
3	Tajima Y, Yamazaki K, Makino R, et al: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res. 12:6469–6479. 2006. View Article : Google Scholar
4	Barrow H, Rhodes JM and Yu LG: The role of galectins in colorectal cancer progression. Int J Cancer. 129:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
5	Alves PM, Godoy GP, Gomes DQ, et al: Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract. 207:236–240. 2011. View Article : Google Scholar : PubMed/NCBI
6	Barrow H, Guo X, Wandall HH, et al: Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI
7	Kamper P, Ludvigsen M, Bendix K, et al: Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 117:6638–6649. 2011. View Article : Google Scholar : PubMed/NCBI
8	Tang CE, Tan T, Li C, et al: Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep. 24:495–500. 2010.PubMed/NCBI
9	Espelt MV, Croci DO, Bacigalupo ML, et al: Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology. 53:2097–2106. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xue X, Lu Z, Tang D, et al: Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an in vitro study on the microenvironment of pancreatic ductal adenocarcinoma. Pancreas. 40:832–839. 2011. View Article : Google Scholar
11	Carlsson MC, Balog CI, Kilsgård O, et al: Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochim Biophys Acta. 1820:1366–1372. 2012. View Article : Google Scholar
12	Kuo PL, Huang MS, Cheng DE, et al: Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem. 287:9753–9764. 2012. View Article : Google Scholar
13	Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK and Dimitroff CJ: Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 188:3127–3137. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gomez-Brouchet A, Mourcin F, Gourraud PA, et al: Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma. Hum Pathol. 41:1220–1230. 2010. View Article : Google Scholar : PubMed/NCBI
15	Dhondge A, Surendran S, Seralathan MV, et al: Cellular alterations and modulation of protein expression in bitumen-challenged human osteoblast cells. Environ Sci Pollut Res Int. 19:4030–4041. 2012. View Article : Google Scholar : PubMed/NCBI
16	Wu H, Chen P, Liao R, et al: Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol. 27:1312–1319. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kim HJ, Jeon HK, Cho YJ, et al: High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wu MH, Hong HC, Hong TM, et al: Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res. 17:1306–1316. 2011. View Article : Google Scholar : PubMed/NCBI
19	Cedeno-Laurent F, Watanabe R, Teague JE, et al: Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood. 119:3534–3538. 2012. View Article : Google Scholar : PubMed/NCBI
20	Satelli A and Rao US: Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett. 301:38–46. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ito K, Stannard K, Gabutero E, et al: Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 31:763–778. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mathieu V, de Lassalle EM, Toelen J, et al: Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol. 132:2245–2254. 2012. View Article : Google Scholar : PubMed/NCBI
23	Chandhanayingyong C, Kim Y, Staples JR, et al: MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma. 2012:4048102012. View Article : Google Scholar : PubMed/NCBI
24	Mirzoeva OK, Das D, Heiser LM, et al: Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69:565–572. 2009. View Article : Google Scholar : PubMed/NCBI
25	Roy SK, Srivastava RK and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
26	Chung LY, Tang SJ, Sun GH, et al: Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res. 18:4037–4047. 2012. View Article : Google Scholar : PubMed/NCBI
27	Tsimaratou K, Kletsas D, Kastrinakis NG, et al: Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J Pathol. 211:331–339. 2007. View Article : Google Scholar : PubMed/NCBI
28	Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI